Abstract

The existence of many background cells and the size overlap between white blood cells (WBCs) and malignant tumor cells (MTCs) pose a challenge for the efficient separation of MTCs from effusions or bloods. Herein, we proposed an inertia-magnetic cell separation (IMCS) device integrating a trapezoidal spiral chip with an immunomagnetic chip for high-throughput, high-recovery, and high-purity separation of MTCs from malignant pleural and peritoneal effusions (MPPEs). First, the effects of flow rate and particle size on separation performances in two separate chips were investigated. Then, the performances of the integrated IMCS device were characterized using blood samples spiked with three different tumor cells (A549, MCF-7, and MDA-MB-231 cells). The results showed that all the three tumor cells were separated from the WBCs with a high-throughput of ∼ 3200 μL/min, a high-recovery ratio of > 90%, and a high-purity of > 70%. Finally, we successfully separated MTCs from four clinical MPPE samples with an average purity of > 70%. As compared with conventional microfluidic devices using single technologies, our IMCS device combines the advantages of both passive size-dependent separation technology and immunomagnetic separation technology and can accurately separate tumor cells from WBCs of comparable sizes at a high throughput. Therefore, we envision that the high-purity MTC separation ability of our IMCS device can improve the sensitivity and efficiency of cytological examination.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.